Clinical trials: in Georgia
Myasthenia Gravis, Generalized
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
- Trial name
- NCT07647510
- Testing
- Claseprubart
- Where
- 12 sites in United States, Georgia and 1 more
- Volunteers
- 195 people
- Sponsor
- Dianthus Therapeutics
Focal Segmental Glomerulosclerosis
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07220083
- Testing
- BI 764198
- Where
- 316 sites in United States, Argentina and 38 more
- Volunteers
- 286 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves…
- Trial name
- NCT07472517
- Testing
- obrixtamig, atezolizumab, carboplatin
- Where
- 243 sites in United States, Argentina and 40 more
- Volunteers
- 670 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
- Conditions
- Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07080242
- Testing
- BL-M14D1
- Where
- 31 sites in United States, Georgia and 1 more
- Volunteers
- 120 people
- Sponsor
- SystImmune Inc.
Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
- Trial name
- CAPTIVATE (NCT06858579)
- Testing
- Claseprubart
- Where
- 201 sites in United States, Argentina and 29 more
- Volunteers
- 256 people
- Sponsor
- Dianthus Therapeutics
Atrial Fibrillation
Coherent Sine Burst (CSE) Electroporation System Pilot Study in Patients With Atrial Fibrillation
To evaluate the safety and efficiency of the Arga Medtech CSE Ablation System in the treatment of atrial fibrillation.
- Trial name
- BURST-AF (NCT05572047)
- Testing
- Arga Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System
- Where
- 3 sites in Croatia, Georgia
- Volunteers
- 101 people
- Sponsor
- Arga Medtech SA
Advanced or Metastatic Non-small Cell Lung Cancer
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
- Trial name
- ALTAIR (NCT06996782)
- Testing
- Rilvegostomig, Cisplatin, Carboplatin
- Where
- 103 sites in United States, Belgium and 18 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study is open to adults who are at least 18 years old living with obesity and have: a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and moderate or advanced…
- Trial name
- NCT06632444
- Testing
- Survodutide
- Where
- 532 sites in United States, Argentina and 35 more
- Volunteers
- 1,800 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or…
- Trial name
- FIBRONEER™-ON (NCT06238622)
- Testing
- Nerandomilast
- Where
- 375 sites in United States, Argentina and 42 more
- Volunteers
- 1,666 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer.
- Trial name
- NCT06806852
- Testing
- BI 770371, Pembrolizumab, Cetuximab
- Where
- 51 sites in United States, Australia and 20 more
- Volunteers
- 91 people
- Sponsor
- Boehringer Ingelheim
Generalized Myasthenia Gravis
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG).
- Trial name
- NIMBLE (NCT05070858)
- Testing
- Pozelimab + Cemdisiran, Cemdisiran, Pozelimab
- Where
- 116 sites in United States, Belgium and 17 more
- Volunteers
- 288 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD.
- Trial name
- Navigator (NCT07684820)
- Testing
- EXPD-101/FXS7553 Dose 1, EXPD-101/FXS7553 Dose 2
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 600 people
- Sponsor
- Expedition Therapeutics, Inc
Metabolic Dysfunction Associated Steatohepatitis
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study is open to adults who are at least 18 years old and have: A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or A confirmed liver disease called metabolic-associated steatohepatitis (MASH) BMI of 27…
- Trial name
- NCT06632457
- Testing
- Survodutide
- Where
- 447 sites in United States, Argentina and 35 more
- Volunteers
- 1,590 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Hypertension, Interstitial Lung Disease
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
- Trial name
- NCT07234032
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 11 sites in United States, Czechia and 6 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Chronic Hepatitis D Infection
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection.
- Trial name
- NCT06907290
- Testing
- Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg
- Where
- 30 sites in United States, Australia and 9 more
- Volunteers
- 150 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Multiple Sclerosis (MS) Primary Progressive
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.
- Trial name
- NCT07067463
- Testing
- Orelabrutinib
- Where
- 76 sites in United States, Bulgaria and 14 more
- Volunteers
- 705 people
- Sponsor
- Zenas BioPharma (USA), LLC
Secondary Progressive Multiple Sclerosis
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with…
- Trial name
- NCT07299019
- Testing
- Orelabrutinib
- Where
- 69 sites in United States, Australia and 14 more
- Volunteers
- 990 people
- Sponsor
- Zenas BioPharma (USA), LLC
Graves Disease
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated.
- Trial name
- VitaliThy (NCT07596849)
- Testing
- efgartigimod PH20 SC
- Where
- 42 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 230 people
- Sponsor
- argenx
Ulcerative Colitis, Inflammatory Bowel Diseases
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
- Trial name
- SKYLINE-UC (NCT07012395)
- Testing
- SPY001, SPY002, SPY003
- Where
- 276 sites in United States, Argentina and 33 more
- Volunteers
- 645 people
- Sponsor
- Spyre Therapeutics, Inc.
Ocular Myasthenia Gravis
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.
- Trial name
- MyVision (NCT07463521)
- Testing
- Rozanolixizumab
- Where
- 29 sites in United States, Canada and 6 more
- Volunteers
- 120 people
- Sponsor
- UCB Biopharma SRL